Pacira BioSciences Inc’s (PCRX) 200-liter manufacturing process for EXPAREL is under FDA review, with a decision anticipated on August 6.Exparel, a long-acting local analgesic is currently manufactured using a 45-liter batch process, and was commercially launched in the United States in April 2012.The full-year EXPAREL net product sales were $413.3 million in 2020 compared to $407.9 million in 2019. PCRX closed Monday’s (Jul.26, 2021) trading at $58.91, up 0.36%.